Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives.

Reply to Letter from Drs. Haider and Ashraf

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

Role of Stem Cell Homing in Myocardial Regeneration

Human Pluripotent Stem Cell-Derived Cardiovascular Progenitors for Heart Regeneration

Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation

A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart

Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering.

Current Status of Induced Pluripotent Stem Cells in Cardiac Tissue Regeneration and Engineering.

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Current Status of Stem Cell Therapy in Heart Failure

The Challenges Of Stem Cell Therapy In Myocardial Infarction And Heart Failure And The Potential Strategies To Improve The Outcomes

Pluripotent Reprogramming and Lineage Reprogramming: Promises and Challenges in Cardiovascular Regeneration

Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells

Concise Review: Heart Regeneration and the Role of Cardiac Stem Cells

Cardiac Progenitor/stem Cells on Myocardial Infarction or Ischemic Heart Disease: What We Have Known from Current Research

Leading Progress in Heart Regeneration and Repair

Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy